Literature DB >> 16880624

Metabolites of hirsuteine and hirsutine, the major indole alkaloids of Uncaria rhynchophylla, in rats.

Takahiro Nakazawa1, Koh-ichi Banba, Kazumasa Hata, Yutaka Nihei, Ayumi Hoshikawa, Keisuke Ohsawa.   

Abstract

The metabolic fate of hirsuteine (HT) and hirsutine (HS), the major indole alkaloids of Uncaria rhynchophylla, was investigated using rats. On HPLC analysis, urine from rats orally administered HT were found to contain two metabolites (HT1 and HT2) together with unchanged HT. Similarly HS also was metabolized to two compounds (HS1 and HS2). Metabolite structures were determined to be 11-hydroxyhirsuteine-11-O-beta-D-glucuronide (HT1), 11-hydroxyhirsuteine (HT2), 11-hydroxyhirsutine-11-O-beta-D-glucuronide (HS1) and 11-hydroxyhirsutine (HS2), based on spectroscopic and chemical data. HT1 and HS1 were also detected in bile from rats administered HT and HS, respectively. Total cumulative urinary excretion within 72 h of oral administration was approximately 14% and 26% of the HT and HS doses, respectively, while total cumulative biliary excretion was 35% and 46%, respectively. HT and HS 11-hydroxylation were catalyzed by rat liver microsomes. This 11-hydroxylation activity was inhibited by addition of SKF-525A (a nonselective CYP inhibitor) or cimetidine (a CYP2C inhibitor). These results indicate that orally administered HT and HS are converted to 11-hydroxy metabolites in rats, and that the metabolites are predominantly excreted in bile rather than urine following glucuronidation. Furthermore, the results suggest that CYP2C enzymes are involved, at least in part, in the specific 11-hydroxylation of HT and HS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880624     DOI: 10.1248/bpb.29.1671

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Urinary metabolites of isorhynchophylline in rats and their neuroprotective activities in the HT22 cell assay.

Authors:  Fangfang Chen; Wen Qi; Jiahong Sun; James W Simpkins; Dan Yuan
Journal:  Fitoterapia       Date:  2014-06-06       Impact factor: 2.882

Review 2.  Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors.

Authors:  Ronald J Y Chen; Tzyy-rong Jinn; Yi-ching Chen; Tse-yu Chung; Wei-hung Yang; Jason T C Tzen
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

3.  Isolation and identification of twelve metabolites of isocorynoxeine in rat urine and their neuroprotective activities in HT22 cell assay.

Authors:  Wen Qi; Fangfang Chen; Jiahong Sun; James W Simpkins; Dan Yuan
Journal:  Planta Med       Date:  2014-12-17       Impact factor: 3.352

4.  Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study.

Authors:  Hiroyuki Kitagawa; Masaya Munekage; Kengo Ichikawa; Ian Fukudome; Eri Munekage; Yuka Takezaki; Takashi Matsumoto; Yasushi Igarashi; Haruo Hanyu; Kazuhiro Hanazaki
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

5.  Metabolic profiling of the Uncaria hook alkaloid geissoschizine methyl ether in rat and human liver microsomes using high-performance liquid chromatography with tandem mass spectrometry.

Authors:  Hirotaka Kushida; Takashi Matsumoto; Yasushi Igarashi; Hiroaki Nishimura; Junko Watanabe; Kazuya Maemura; Yoshio Kase
Journal:  Molecules       Date:  2015-01-27       Impact factor: 4.411

6.  Tissue Distribution of Hirsutine and Hirsuteine in Mice by Ultrahigh-Performance Liquid Chromatography-Mass Spectrometry.

Authors:  Quan Zhou; Jianshe Ma; Limei Chen
Journal:  J Anal Methods Chem       Date:  2020-04-21       Impact factor: 2.193

Review 7.  Properties, Pharmacology, and Pharmacokinetics of Active Indole and Oxindole Alkaloids in Uncaria Hook.

Authors:  Hirotaka Kushida; Takashi Matsumoto; Yasushi Ikarashi
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.